Leah J. McGrath

Leah J. McGrath

Auto-generated profile, based on publicly available information

Leah J. McGrath

Medical Evidence Generation, Pfizer Inc. , New York, NY 10001

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2020 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
PDF file
LMLeah J. McGrath
Leah J. McGrath
LSLeslie Spangler
Leslie Spangler
JCJeffrey R. Curtis
Jeffrey R. Curtis
VEVera Ehrenstein
Vera Ehrenstein
HSHenrik T. Sørensen
Henrik T. Sørensen
MBM. Alan Brookhart
M. Alan Brookhart

18 April 2021 in Advances in Therapy
Verified
Journal Article
Open access
PDF file
STSara J Snell Taylor
Sara J Snell Taylor
CNCarrie M Nielson
Carrie M Nielson
ABAlexander Breskin
Alexander Breskin
BSBradley Saul
Bradley Saul
YYYING YU
YING YU
LMLeah J McGrath
Leah J McGrath
Introduction Romiplostim has been approved in Europe since 2009 to treat patients with chronic primary immune thrombocytopenia (ITP). Using real-world data from seven European countries, we measured the effectiveness and safety outcomes within 24 weeks following romiplostim initiation by duration of ITP: less than 3 months (“newly diagnosed”), 3–12 months (“persistent”), and more than 12 months (“chronic”). Methods Adults with ITP and ≥ 1 romiplostim administration between 2009 and 2012 were included. Endpoints included durable platelet response, median platelet count, rescue therapy, bleeding and adverse events. We used inverse probability of censoring weighted estimators to estimate cumulative risk of each outcome. There were 64 newly diagnosed, 50 persistent, and 226 chronic ITP patients at romiplostim initiation. Results Durable platelet response at 24 weeks ranged from 32% [confidence interval (CI): 18–46%] in newly diagnosed patients to 53% (CI 37–68%) in persistent patients. Median platelet count during follow-up ranged from 88 (CI 80–96) × 109/L in chronic patients to 131 (CI 102–160) × 109/L in newly diagnosed patients. Conclusion Regardless of ITP duration, over half of patients discontinued concomitant ITP medications. Few adverse events were observed. Although only approved for chronic patients, estimates of the romiplostim treatment effect were similar across patients being managed in European clinical practice, regardless of ITP duration at romiplostim initiation.

1 May 2020 in Clinical Epidemiology
Verified
Journal Article
Open access
PDF file
LMLeah J McGrath
Leah J McGrath
KKKarynsa Kilpatrick
Karynsa Kilpatrick
RORobert A Overman
Robert A Overman
DRDiane Reams
Diane Reams
ASAnjali Sharma
Anjali Sharma
MBM Alan Brookhart
M Alan Brookhart
Purpose: Patients with immune thrombocytopenia (ITP) have low platelet counts and an increased risk of bleeding. We described treatment patterns and clinical outcomes in routine practice in the United States (US). Patients and Methods: Using electronic health record data from hematology/oncology clinics linked to administrative claims in the US, we studied 447 adults newly diagnosed with primary ITP from 2011 to 2016. Patients with a secondary cause of thrombocytopenia were excluded. The incidence of ITP treatment initiation, bleeding events, and rescue therapy use were estimated using competing risk models. Results: At 1-year post-ITP diagnosis, 50% of patients were prescribed an oral corticosteroid, with the majority being prescribed immediately following diagnosis. Of the more common second-line options, rituximab use was the most frequent (1-year cumulative incidence: 16% [95% confidence interval: 12, 19]), followed by romiplostim (9% [7, 12] and eltrombopag (5% [3, 8]). Use of these drugs was similar at 2 years post-diagnosis. At 6 months post-ITP treatment initiation, the cumulative incidence of bleeding was similar among eltrombopag and romiplostim initiators (17% [6, 33] and 19% [9, 31], respectively) and was slightly lower in rituximab users (12% [6, 20]). However, during this same timeframe, rituximab users had a higher incidence of rescue therapy use (48% [36, 58] versus 29% [14, 46] in eltrombopag and 26% [14, 39] in romiplostim users). Although splenectomy was rare, at 6 months post-surgery nearly 20% had experienced a bleed and nearly 20% had required rescue. Conclusion: This study describes the health trajectory of adults with ITP who are managed in hematology clinics in the US and could inform the design of non-interventional studies of comparative effectiveness among treatments.

1 July 2020 in Vaccine
Verified
Journal Article
Closed access
JLJ. Bradley Layton
J. Bradley Layton
LMLeah J. McGrath
Leah J. McGrath
JSJohn M. Sahrmann
John M. Sahrmann
YMYinjiao Ma
Yinjiao Ma
VDVikas R. Dharnidharka
Vikas R. Dharnidharka
ABAnne M. Butler
Anne M. Butler

2 November 2022 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
LMLeah J. McGrath
Leah J. McGrath
HFHolly M. F Frost
Holly M. F Frost
JNJason G. Newland
Jason G. Newland
COCaroline A. O'Neil
Caroline A. O'Neil
JSJohn M. Sahrmann
John M. Sahrmann
ABAnne M. Butler
Anne M. Butler

1 September 2018 in Clinical Epidemiology
Verified
Journal Article
Open access
PDF file
LMLeah J McGrath
Leah J McGrath
RORobert A Overman
Robert A Overman
DRDiane Reams
Diane Reams
KCKarynsa Cetin
Karynsa Cetin
ALAlexander Liede
Alexander Liede
RHRohini K Hernandez
Rohini K Hernandez
Purpose: Bone-modifying agents (BMAs) are recommended for women with bone metastasis from breast cancer to prevent skeletal-related events. We examined the usage patterns and identified the factors associated with the use of BMAs (denosumab and intravenous bisphosphonates) among women in the US. Patients and methods: Electronic health records from oncology clinics were used to identify women diagnosed with bone metastasis from breast cancer between 2013 and 2014. Patients were excluded if they had recently used a BMA or had concurrent cancer at an additional primary site. The incidence of BMA initiation, interruption, and reinitiation were estimated using competing risk regression models. A generalized linear model was used to estimate risk factors for treatment initiation and interruption. Results: There were 589 women diagnosed with bone metastasis from breast cancer. By 1 year, 68% of these patients (95% CI: 64%, 71%) had initiated treatment with a BMA. Denosumab and zoledronic acid were the most commonly used agents, whereas pamidronate was used infrequently. Young women were more likely to initiate a BMA than older women (adjusted risk difference: 6.4 [95% CI: 1.5, 10.9]). Of the 412 patients who initiated a BMA, 46% (95% CI: 41%, 51%) experienced an interruption within 1 year. Seventy-four percent (95% CI: 68%, 79%) of patients who interrupted their treatment had reinitiated therapy within 1 year of interruption. Conclusion: The majority of women diagnosed with bone metastasis from breast cancer initiate a BMA within 1 year of diagnosis, but a large proportion, particularly among the elderly, do not use these therapies.